| Entry |
|
|---|
| Name |
Vorasidenib citrate (USAN);
Vorasidenib citric acid hydrate (JAN);
Voranigo (TN) |
|---|
| Product |
|
|---|
| Formula |
(C14H13ClF6N6)2. C6H8O7. H2O
|
|---|
| Exact mass |
1038.1964
|
|---|
| Mol weight |
1039.61
|
|---|
| Structure |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG03113): | D11835<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Isocitrate dehydrogenase inhibitor |
|---|
| Disease |
Astrocytoma (susceptible IDH1 or IDH2 mutation) [DS: H00042] Oligodendroglioma (susceptible IDH1 or IDH2 mutation) [DS: H00042] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XM Isocitrate dehydrogenase (IDH) inhibitors
L01XM04 Vorasidenib
D11835 Vorasidenib citrate (USAN) <US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11835 Vorasidenib citrate (USAN); Vorasidenib citric acid hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG03328 Isocitrate dehydrogenase inhibitor
DG03113 Vorasidenib
D11835 Vorasidenib citrate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
DG02919 CYP2B6 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
DG02918 CYP2C8 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
DG01642 CYP2C9 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
DG01639 CYP2C19 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
DG01644 CYP2D6 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
DG01633 CYP3A/CYP3A4 substrate
DG03113 Vorasidenib
D11835 Vorasidenib citrate
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
IDH
D11835 Vorasidenib citrate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11835
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11835
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11835
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11835
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11835
Drug groups [BR:br08330]
Antineoplastic
DG03328 Isocitrate dehydrogenase inhibitor
DG03113 Vorasidenib
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG03113 Vorasidenib
DG02919 CYP2B6 substrate
DG03113 Vorasidenib
DG02918 CYP2C8 substrate
DG03113 Vorasidenib
DG01642 CYP2C9 substrate
DG03113 Vorasidenib
DG01639 CYP2C19 substrate
DG03113 Vorasidenib
DG01644 CYP2D6 substrate
DG03113 Vorasidenib
DG01633 CYP3A/CYP3A4 substrate
DG03113 Vorasidenib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 68
1 C8y C 17.4332 -18.9797
2 N5x N 17.4332 -17.5738
3 C8y C 18.6282 -16.8709
4 N5x N 19.8935 -17.5738
5 C8y C 19.8935 -18.9797
6 N5x N 18.6282 -19.6826
7 N1b N 21.0885 -19.6826
8 C1c C 22.2835 -18.9797
9 N1b N 16.2382 -19.6826
10 C1c C 15.0432 -18.9797
11 C1a C 13.8482 -19.6826
12 C1d C 15.0432 -17.5738
13 C8y C 18.6282 -15.4650
14 N5x N 17.4332 -14.7620
15 C8y C 17.4332 -13.3562
16 C8x C 18.6282 -12.6532
17 C8x C 19.8935 -13.3562
18 C8x C 19.8935 -14.7620
19 X Cl 16.2382 -12.6532
20 X F 13.8482 -16.8709
21 X F 16.2382 -16.8709
22 X F 13.8482 -18.2767
23 C1a C 23.4785 -19.6826
24 C1d C 22.2835 -17.5738
25 X F 23.4785 -16.8709
26 X F 21.0885 -16.8709
27 X F 23.4785 -18.2767
28 C1d C 30.9448 -14.7714
29 C1b C 29.8245 -15.4715
30 C1b C 32.1350 -15.4715
31 C6a C 31.6449 -13.6511
32 O1a O 30.2446 -13.6511
33 C6a C 28.6343 -14.8414
34 C6a C 32.1350 -16.8718
35 O6a O 30.9448 -12.4609
36 O6a O 33.1852 -13.6511
37 O6a O 27.3740 -15.5415
38 O6a O 28.6343 -13.5111
39 O6a O 33.5353 -17.6419
40 O6a O 30.9448 -17.6419
41 O0 O 31.0800 -20.2300
42 C8y C 17.4332 -18.9797
43 N5x N 17.4332 -17.5738
44 C8y C 18.6282 -16.8709
45 N5x N 19.8935 -17.5738
46 C8y C 19.8935 -18.9797
47 N5x N 18.6282 -19.6826
48 N1b N 21.0885 -19.6826
49 C1c C 22.2835 -18.9797
50 C1a C 23.4785 -19.6826
51 C1d C 22.2835 -17.5738
52 X F 23.4785 -16.8709
53 X F 21.0885 -16.8709
54 X F 23.4785 -18.2767
55 C8y C 18.6282 -15.4650
56 N5x N 17.4332 -14.7620
57 C8y C 17.4332 -13.3562
58 C8x C 18.6282 -12.6532
59 C8x C 19.8935 -13.3562
60 C8x C 19.8935 -14.7620
61 X Cl 16.2382 -12.6532
62 N1b N 16.2382 -19.6826
63 C1c C 15.0432 -18.9797
64 C1a C 13.8482 -19.6826
65 C1d C 15.0432 -17.5738
66 X F 13.8482 -16.8709
67 X F 16.2382 -16.8709
68 X F 13.8482 -18.2767
BOND 68
1 28 29 1
2 28 30 1
3 28 31 1
4 28 32 1
5 29 33 1
6 30 34 1
7 31 35 1
8 31 36 2
9 33 37 1
10 33 38 2
11 34 39 1
12 34 40 2
13 1 2 2
14 2 3 1
15 3 4 2
16 4 5 1
17 5 6 2
18 1 6 1
19 5 7 1
20 7 8 1
21 1 9 1
22 9 10 1
23 10 11 1 #Down
24 10 12 1
25 3 13 1
26 13 14 2
27 14 15 1
28 15 16 2
29 16 17 1
30 17 18 2
31 13 18 1
32 15 19 1
33 12 20 1
34 12 21 1
35 12 22 1
36 8 23 1 #Up
37 8 24 1
38 24 25 1
39 24 26 1
40 24 27 1
41 42 43 2
42 43 44 1
43 44 45 2
44 45 46 1
45 46 47 2
46 42 47 1
47 46 48 1
48 48 49 1
49 42 62 1
50 62 63 1
51 63 64 1 #Down
52 63 65 1
53 44 55 1
54 55 56 2
55 56 57 1
56 57 58 2
57 58 59 1
58 59 60 2
59 55 60 1
60 57 61 1
61 65 66 1
62 65 67 1
63 65 68 1
64 49 50 1 #Up
65 49 51 1
66 51 52 1
67 51 53 1
68 51 54 1
BRACKET 1 11.2700 -21.1400 11.2700 -11.6200
1 25.3400 -11.6200 25.3400 -21.1400
1 2
ORIGINAL 1 1 2 3 4 5 6 7 8 23 24 25 26 27 13 14 15
1 16 17 18 19 9 10 11 12 20 21 22
REPEAT 1 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
1 58 59 60 61 62 63 64 65 66 67 68
|
|---|
